Kalbe Farma Tbk PT banner

Kalbe Farma Tbk PT
OTC:PTKFF

Watchlist Manager
Kalbe Farma Tbk PT Logo
Kalbe Farma Tbk PT
OTC:PTKFF
Watchlist
Price: 0.0403 USD Market Closed
Market Cap: $1.9B

Wall St Price Targets

PTKFF Price Targets Summary
Kalbe Farma Tbk PT

Wall Street analysts forecast PTKFF stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for PTKFF is 0.0677 USD with a low forecast of 0.0425 USD and a high forecast of 0.0922 USD.

Lowest Forecast
Price Target
0.0425 USD
6% Upside
Average Forecast
Price Target
0.0677 USD
68% Upside
Highest Forecast
Price Target
0.0922 USD
129% Upside
Kalbe Farma Tbk PT Competitors:
Price Targets
4726
Mycenax Biotech Inc
76% Upside
PAYX
Paychex Inc
-7% Downside
6657
Energenesis Biomedical Co Ltd
41% Upside

Revenue
Forecast

8% / Year
Past Growth
9% / Year
Estimated Growth
Estimates Accuracy
-2%
Average Miss
8% / Year
Past Growth
9% / Year
Estimated Growth
Estimates Accuracy
-2%
Average Miss

Over the last 13 years, the compound annual growth rate for Revenue has been 8%. The projected CAGR for the next 3 years is 9%.

Gross Profit
Forecast

6% / Year
Past Growth
11% / Year
Estimated Growth
Estimates Accuracy
-4%
Average Miss
6% / Year
Past Growth
11% / Year
Estimated Growth
Estimates Accuracy
-4%
Average Miss

Over the last 13 years, the compound annual growth rate for Gross Profit has been 6%. The projected CAGR for the next 3 years is 11%.

Operating Income
Forecast

6% / Year
Past Growth
6% / Year
Estimated Growth
Estimates Accuracy
-3%
Average Miss
6% / Year
Past Growth
6% / Year
Estimated Growth
Estimates Accuracy
-3%
Average Miss

Over the last 13 years, the compound annual growth rate for Operating Income has been 6%. The projected CAGR for the next 3 years is 6%.

Pre-Tax Income
Forecast

6% / Year
Past Growth
3% / Year
Estimated Growth
Estimates Accuracy
-2%
Average Miss
6% / Year
Past Growth
3% / Year
Estimated Growth
Estimates Accuracy
-2%
Average Miss

Over the last 13 years, the compound annual growth rate for Pre-Tax Income has been 6%. The projected CAGR for the next 3 years is 3%.

Net Income
Forecast

6% / Year
Past Growth
8% / Year
Estimated Growth
Estimates Accuracy
-3%
Average Miss
6% / Year
Past Growth
8% / Year
Estimated Growth
Estimates Accuracy
-3%
Average Miss

Over the last 13 years, the compound annual growth rate for Net Income has been 6%. The projected CAGR for the next 3 years is 8%.

Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.

What is PTKFF's stock price target?
Price Target
0.0677 USD

According to Wall Street analysts, the average 1-year price target for PTKFF is 0.0677 USD with a low forecast of 0.0425 USD and a high forecast of 0.0922 USD.

What is the Revenue forecast for Kalbe Farma Tbk PT?
Projected CAGR
9%

Over the last 13 years, the compound annual growth rate for Revenue has been 8%. The projected CAGR for the next 3 years is 9%.

What is the Gross Profit forecast for Kalbe Farma Tbk PT?
Projected CAGR
11%

Over the last 13 years, the compound annual growth rate for Gross Profit has been 6%. The projected CAGR for the next 3 years is 11%.

What is the Operating Income forecast for Kalbe Farma Tbk PT?
Projected CAGR
6%

Over the last 13 years, the compound annual growth rate for Operating Income has been 6%. The projected CAGR for the next 3 years is 6%.

What is the Pre-Tax Income forecast for Kalbe Farma Tbk PT?
Projected CAGR
3%

Over the last 13 years, the compound annual growth rate for Pre-Tax Income has been 6%. The projected CAGR for the next 3 years is 3%.

What is the Net Income forecast for Kalbe Farma Tbk PT?
Projected CAGR
8%

Over the last 13 years, the compound annual growth rate for Net Income has been 6%. The projected CAGR for the next 3 years is 8%.

Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett